Nivolumab after selective internal radiation therapy for the treatment of hepatocellular carcinoma: a phase 2, single-arm study

PURPOSE: To evaluate the safety and efficacy of selective internal radiation therapy (SIRT) in combination with a PD-1 inhibitor in patients with unresectable hepatocellular carcinoma (uHCC) and liver-only disease ineligible for chemoembolization. PATIENTS AND METHODS: NASIR-HCC is a single-arm, mul...

Descripción completa

Detalles Bibliográficos
Autores principales: de la Torre-Aláez, Manuel, Matilla, Ana, Varela, Maria, Iñarrairaegui, Mercedes, Reig, Maria, Lledó, Jose Luis, Arenas, Juan Ignacio, Lorente, Sara, Testillano, Milagros, Márquez, Laura, Da Fonseca, Leonardo, Argemí, Josepmaria, Gómez-Martin, Carlos, Rodriguez-Fraile, Macarena, Bilbao, Jose I, Sangro, Bruno
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2022
Materias:
Clinical/Translational Cancer Immunotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9716796/
https://www.ncbi.nlm.nih.gov/pubmed/36450386
http://dx.doi.org/10.1136/jitc-2022-005457

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9716796/
https://www.ncbi.nlm.nih.gov/pubmed/36450386
http://dx.doi.org/10.1136/jitc-2022-005457

Ejemplares similares